Drug major Sun Pharma has completed the acquisition of Japan-based Pola Pharma in order to strengthen its presence in dermatology segment across the globe. Pola Pharma is engaged in the manufacture, research and development, sale and distribution of branded and generic products in Japan.
Sun Pharma’s BSE filing stated, "Sun Pharma has completed all the necessary formalities, the acquisition of 100% shares of Pola Pharma Inc., Japan, via the company's wholly owned subsidiary."
Sun Pharma had entered into a definitive agreement to buy Pola Pharma.
The portfolio of Pola Pharma mainly comprises of dermatology products. The company has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables.
Sun Pharma had entered the Japanese prescription market in 2016 with the acquisition of 14 established prescription brands from Novartis.
